PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.99%
R&D growth 1.1-1.25x AGEN's 39.50%. Bill Ackman would demand evidence of superior returns.
-4.08%
G&A reduction while AGEN shows 9.13% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
80.19%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
21.99%
Operating expenses growth above 1.5x AGEN's 9.13%. Michael Burry would check for inefficiency.
21.99%
Total costs growth 50-75% of AGEN's 29.77%. Bruce Berkowitz would examine efficiency.
No Data
No Data available this quarter, please select a different quarter.
80.19%
D&A growth 50-75% of AGEN's 124.52%. Bruce Berkowitz would examine asset strategy.
32.89%
EBITDA growth exceeding 1.5x AGEN's 13.84%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-21.99%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
198.65%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
32.68%
Pre-tax income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.68%
Net income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
32.51%
EPS growth while AGEN declines. John Neff would investigate advantages.
32.51%
Diluted EPS growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.